GlucoTrack, Inc. develops medical technology for people with diabetes, centered on a long-term, fully implantable continuous blood glucose monitoring system. Company news commonly covers the CBGM platform, FDA Investigational Device Exemption activity, preclinical and clinical-study disclosures, and peer-reviewed publications on sensor stability, accuracy, and implantable device performance.
Updates also include intellectual-property developments for proprietary sensor chemistry, intravascular lead design, and low-power electronics, along with financial results, research and development spending, capital actions, and conference presentations tied to the company’s diabetes device strategy.
Glucotrack (Nasdaq: GCTK) has completed its strategic business combination with Lōkahi Therapeutics, creating a publicly listed platform focused on identifying, acquiring, and advancing differentiated healthcare assets. The structure makes Lōkahi the operating and controlling business, using Glucotrack’s public listing to support long-term growth and capital access.
Lōkahi’s late-stage clinical program and ai²-driven asset sourcing platform are being integrated with Glucotrack’s technology infrastructure. Lōkahi securityholders received Glucotrack common and convertible preferred stock that, after stockholder approvals and Nasdaq requirements, is expected to convert into common equity, giving them about 90% of the combined company on a fully diluted basis. A planned private placement is intended to bolster capital, while Glucotrack’s continuous blood glucose monitoring business will continue as a wholly owned subsidiary. Erik Emerson becomes CEO of the combined company, with Paul Goode as CTO and CEO of the CBGM subsidiary.
Glucotrack (Nasdaq:GCTK) received a USPTO Notice of Allowance for a patent application titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient.” The allowed claims expand protection of its fully implantable continuous blood glucose monitoring (CBGM) platform.
The filing adds to three CBGM patents issued in late 2025 and covers intravascular sensing leads, electronics assemblies, electrode configurations, and implantation methods. Glucotrack’s CBGM is designed as a long-term implantable system with no wearable component, targeting up to three years of continuous, blood-based glucose monitoring with real-time readings.
Glucotrack (Nasdaq:GCTK) will showcase its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans, June 5–8, 2026.
The company highlights direct blood measurements, multi-year implant longevity, no on-body wearables, new peer-reviewed data, and a recent FDA IDE submission.
Glucotrack (Nasdaq:GCTK) reported first quarter 2026 results and progress on its fully implantable continuous blood glucose monitoring (CBGM) program.
Key updates include FDA IDE submission for a U.S. clinical study targeted for 2H 2026, supportive peer-reviewed data, debt reduction, and lower net loss year-over-year.
Glucotrack (Nasdaq: GCTK) submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration on May 7, 2026 to initiate a U.S. clinical study of its fully implantable continuous blood glucose monitoring (CBGM) system. The filing follows preclinical testing and iterative design work and, if approved, would allow clinical evaluation of a long‑term, blood‑based CGM without an on‑body wearable.
Glucotrack says it will proceed with the U.S. study after FDA review and approval and intends to generate clinical data to support future regulatory advancement.
Glucotrack (Nasdaq: GCTK) published a peer-reviewed Journal of Diabetes Research study reporting long-term accuracy and stability of its fully implantable continuous blood glucose monitor in an in-vivo ovine model.
The study implanted 34 devices in 17 sheep for up to 240 days, reporting a weighted average MARD 6.8%, consistent sensing, and no device-related adverse safety events; company also cites first-in-human MARD 7.7% with 99% data capture.
Glucotrack (Nasdaq: GCTK) announced a peer‑reviewed publication in IEEE Sensors Journal (published April 7, 2026) reporting the first year‑long in‑vitro measurement of glucose oxidase deactivation in electrochemical sensors.
The study, done with TTP (UK), examined sensors built to mimic ~two‑year‑old devices and supports the feasibility of long‑life implantable continuous blood glucose monitoring. Glucotrack cited prior first‑in‑human results (MARD 7.7%, 99% data capture) and said the work supports near‑term IDE submission efforts.
Glucotrack (Nasdaq: GCTK) reported 2025 results and development progress on its fully implantable continuous blood glucose monitoring (CBGM) platform. The company received three USPTO patents, completed a $4.0 million private placement, held cash of $7.4 million at year-end, and plans an IDE filing in Q2 2026 to support a U.S. clinical trial in H2 2026.
Full‑year 2025 R&D was $9.8M, G&A $6.3M, and net loss was $19.4M versus $22.6M in 2024. An Australian multicenter feasibility study is underway.
Glucotrack (Nasdaq: GCTK) plans to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 to support a U.S. clinical trial for its fully implantable continuous blood glucose monitoring (CBGM) system.
Key 2025 milestones: a 10‑patient Brazil first‑in‑human study (Dec 13, 2024–Jan 31, 2025) showing MARD 7.7%, 99% data capture, no device- or procedure-related serious adverse events, an Australia feasibility study, and three US patents issued Oct–Nov 2025 (sensor chemistry, intravascular lead, low‑power electronics). US study initiation is planned for H2 2026, subject to FDA IDE approval.
Glucotrack (Nasdaq: GCTK) will present at LSI USA ’26 in Dana Point, California, March 16–20, 2026. The company presentation is scheduled for Tuesday, March 17 at 8:15 a.m. PT.
CEO Paul V. Goode, PhD, will introduce Glucotrack’s continuous blood glucose monitor (CBGM) technology, share positive first-in-human study results, and outline regulatory and U.S. commercialization plans toward a clinical trial, emphasizing a fully implantable, patient-centric device designed to reduce daily burden for people with diabetes.